Levocetirizine Dihydrochloride Patent Expiration

Levocetirizine Dihydrochloride was first introduced by Chattem Inc Dba Sanofi Consumer Healthcare in its drug Xyzal on May 25, 2007. Another drug containing Levocetirizine Dihydrochloride is Xyzal Allergy 24Hr. 21 different companies have introduced drugs containing Levocetirizine Dihydrochloride.


Levocetirizine Dihydrochloride Patents

Given below is the list of patents protecting Levocetirizine Dihydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Xyzal Allergy 24hr US8633194 Pharmaceutical composition of piperazine derivatives Oct 16, 2027 Chattem Sanofi
Xyzal US5698558

(Pediatric)

Methods for treating allergic disorders using optically pure (-) cetirizine Jan 26, 2014

(Expired)

Chattem Sanofi
Xyzal US5698558 Methods for treating allergic disorders using optically pure (-) cetirizine Jul 26, 2013

(Expired)

Chattem Sanofi



A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Levocetirizine Dihydrochloride's patents.

Given below is the list recent legal activities going on the following patents of Levocetirizine Dihydrochloride.

Activity Date Patent Number
Patent litigations
Review Certificate Mailed 16 Aug, 2021 US8633194
Review Certificate 22 Jul, 2021 US8633194
Payment of Maintenance Fee, 8th Year, Large Entity 07 Jul, 2021 US8633194
Termination or Final Written Decision 09 Jun, 2020 US8633194
Request for Trial Granted 15 Jul, 2019 US8633194
Petition Requesting Trial 13 Dec, 2018 US8633194
Patent Issue Date Used in PTA Calculation 21 Jan, 2014 US8633194
Recordation of Patent Grant Mailed 21 Jan, 2014 US8633194
Issue Notification Mailed 31 Dec, 2013 US8633194
Dispatch to FDC 20 Dec, 2013 US8633194


Levocetirizine Dihydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Levocetirizine Dihydrochloride Generic API Manufacturers

Several generic applications have been filed for Levocetirizine Dihydrochloride. The first generic version for Levocetirizine Dihydrochloride was by Synthon Bv and was approved on Nov 26, 2010. And the latest generic version is by Ipca Laboratories Ltd and was approved on May 6, 2024.

Given below is the list of companies who have filed for Levocetirizine Dihydrochloride generic, along with the locations of their manufacturing plants worldwide.